New drug duo aims to wake up immune system against hard-to-treat cancers

NCT ID NCT05082259

First seen Feb 14, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumours, including cervical and triple-negative breast cancer. The goal is to see if blocking certain proteins can make cancer cells die in a way that triggers a stronger immune attack. About 61 participants will take part to find the safest dose and check for early signs of tumour shrinkage.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cambridge University Hospitals NHS Trust

    RECRUITING

    Cambridge, CB2 0QQ, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Royal Marden NHS Foundation Trust - Drug Development Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Phone: •••-•••-••••

  • The Royal Marsden NHS Foundation Trust - Breast Unit

    RECRUITING

    Sutton, SM2 5PT, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.